47. Buerger disease
7 clinical trials,   9 drugs   (DrugBank: 4 drugs),   4 drug target genes,   13 drug target pathways
Searched query = "Buerger disease", "Thromboangiitis obliterans"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02501018 (ClinicalTrials.gov) | November 1, 2017 | 14/7/2015 | Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) | A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD) | Critical Limb Ischemia;Buerger Disease;Thromboangiitis Obliterans;Atherosclerosis Obliterans | Biological: CLBS12;Drug: SOC | Caladrius Biosciences, Inc. | NULL | Recruiting | 20 Years | 85 Years | All | 35 | Phase 2 | Japan |